RecruitingPhase 1NCT05936359

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Sponsor

Incyte Corporation

Enrollment

225 participants

Start Date

Sep 25, 2023

Study Type

INTERVENTIONAL

Conditions

Myeloproliferative Neoplasms

Summary

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INCA033989 and a drug called Ruxolitinib for people with myeloproliferative neoplasms. The study is currently recruiting participants at 29 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA033989

INCA033989 will be administered at protocol defined dose.

DRUGRuxolitinib

Rux will be administered according to Prescribing Information/SmPC.

Locations(29)

Royal Brisbane and Women'S Hospital

Herston, Queensland, Australia

Royal Adelaide Hospital

Adelaide, South Australia, Australia

Peter Maccallum Cancer Centre

Melbourne, Victoria, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Princess Margaret Cancer Center

Toronto, Ontario, Canada

Hopital Maisonneuve-Rosemont, Montreal, Qc

Montreal, Quebec, Canada

Odense University Hospital

Odense C, Denmark

Sjaellands Universitetshospital

Roskilde, Denmark

Vejle Hospital

Vejle, Denmark

Institut Bergonie

Bordeaux, France

Chu Nimes

Nîmes, France

Hospital Saint Louis

Paris, France

Institut Gustave Roussy

Villejuif, France

University Medical Center Rwth Aachen

Aachen, Germany

Universitatsklinikum Halle (Saale)

Halle, Germany

Universitätsklinikum Ulm

Ulm, Germany

Aou Policlinico S. Orsola-Malpighi

Bologna, Italy

Azienda Ospedaliero-Universitaria Careggi (Aouc)

Florence, Italy

Fondazione Irccs Ca Granda Ospedale Maggiore

Milan, Italy

National Cancer Center Hospital East

Chiba-ken, Japan

Kagoshima University Hospital

Kagoshima, Japan

Osaka Metropolitan University Hospital

Osaka, Japan

Nippon Medical School Hospital

Tokyo, Japan

Mie University Hospital

Tsu, Japan

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitari I Politecnic La Fe

Valencia, Spain

Guys and St Thomas Nhs Foundation Trust

London, United Kingdom

The Christie Nhs Foundation Trust Uk

Manchester, United Kingdom

University of Oxford

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05936359

Related Trials

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT0700811826 locations

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT0744169454 locations

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT033149741 location

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT0631359330 locations

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0603400213 locations